Pfizer has indicated that they will not be making a submission to NICE for the above indication until the outcome of the palboclicib plus an aromatase inhibitor appraisal [ID915] is final. In the meantime appraisal [ID916] will be suspended while NICE considers the options for rescheduling.
 
Status Suspended
Process STA pre-2018
ID number 916

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 February 2017 Suspended, Pfizer has indicated that they will not be making a submission to NICE for the above indication until the outcome of the palboclicib plus an aromatase inhibitor appraisal [ID915] is final. In the meantime appraisal [ID916] will be suspended while NICE considers the options for rescheduling.
23 November 2016 The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has now been rescheduled. The first committee meeting will take place in June 2017.
20 October 2016 The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has been suspended at the request of Pfizer. The Company submission of a value proposition for palbociclib after endocrine therapy will follow after the outcome of the appraisal of palbociclib for previously untreated disease [ID915] is known.
06 October 2016 Invitation to participate
13 May 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance